BioVie (BIVI) Competitors $1.18 -0.15 (-11.28%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.42%) As of 03/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BIVI vs. VIRI, MIST, ATOS, COYA, CRDL, CABA, CLYM, TLSA, ACOG, and JMACShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Virios Therapeutics (VIRI), Milestone Pharmaceuticals (MIST), Atossa Therapeutics (ATOS), Coya Therapeutics (COYA), Cardiol Therapeutics (CRDL), Cabaletta Bio (CABA), Climb Bio (CLYM), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Virios Therapeutics Milestone Pharmaceuticals Atossa Therapeutics Coya Therapeutics Cardiol Therapeutics Cabaletta Bio Climb Bio Tiziana Life Sciences Alpha Cognition Maxpro Capital Acquisition Virios Therapeutics (NASDAQ:VIRI) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Do analysts prefer VIRI or BIVI? Virios Therapeutics presently has a consensus target price of $3.00, suggesting a potential downside of 37.37%. BioVie has a consensus target price of $3.00, suggesting a potential upside of 154.24%. Given BioVie's stronger consensus rating and higher possible upside, analysts clearly believe BioVie is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer VIRI or BIVI? BioVie received 14 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 65.38% of users gave BioVie an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% BioVieOutperform Votes1765.38% Underperform Votes934.62% Is VIRI or BIVI more profitable? Virios Therapeutics' return on equity of -130.33% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% BioVie N/A -134.07%-93.44% Do institutionals and insiders believe in VIRI or BIVI? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 4.0% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer VIRI or BIVI? In the previous week, BioVie had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for BioVie and 0 mentions for Virios Therapeutics. BioVie's average media sentiment score of 0.44 beat Virios Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral BioVie Neutral Which has more risk & volatility, VIRI or BIVI? Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Which has better valuation & earnings, VIRI or BIVI? Virios Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-17.74BioVieN/AN/A-$32.12M-$9.76-0.12 SummaryBioVie beats Virios Therapeutics on 8 of the 14 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.77M$7.21B$5.81B$8.43BDividend YieldN/A2.79%4.76%3.97%P/E Ratio-0.126.1524.9419.24Price / SalesN/A187.68376.51110.22Price / CashN/A65.6738.0534.58Price / Book0.466.447.374.28Net Income-$32.12M$139.03M$3.18B$247.04M7 Day Performance-15.71%-3.52%-2.91%-3.25%1 Month Performance-32.18%-9.24%-6.80%-6.55%1 Year Performance10.80%-12.95%12.66%4.01% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie1.9185 of 5 stars$1.18-11.3%$3.00+154.2%-37.6%$21.77MN/A-0.1210Short Interest ↑VIRIVirios TherapeuticsN/A$5.36-8.8%$3.00-44.0%+1,301.8%$103.22MN/A-19.855MISTMilestone Pharmaceuticals3.0852 of 5 stars$1.89-7.4%$13.00+587.8%+2.5%$100.79M$1M-2.3330Short Interest ↓ATOSAtossa Therapeutics1.3211 of 5 stars$0.78-1.3%$7.00+792.3%-25.9%$98.69MN/A-3.578COYACoya Therapeutics1.953 of 5 stars$5.90-8.0%$16.25+175.4%-25.6%$98.57M$9.55M-9.086High Trading VolumeCRDLCardiol Therapeutics2.032 of 5 stars$1.17-2.5%$8.40+617.9%-44.4%$96.65MN/A-3.0020CABACabaletta Bio2.2864 of 5 stars$1.96-4.9%$22.71+1,058.9%-93.0%$95.81MN/A-0.9150CLYMClimb Bio3.1369 of 5 stars$1.42-3.4%$10.00+604.2%N/A$95.45MN/A-0.679TLSATiziana Life Sciences1.3072 of 5 stars$0.91+10.4%N/A+140.4%$95.39MN/A0.008Short Interest ↓ACOGAlpha CognitionN/A$5.94-5.4%N/AN/A$95.16MN/A-2.32N/AJMACMaxpro Capital AcquisitionN/A$7.02-7.6%N/A+715.8%$94.27MN/A0.002,021 Related Companies and Tools Related Companies Virios Therapeutics Competitors Milestone Pharmaceuticals Competitors Atossa Therapeutics Competitors Coya Therapeutics Competitors Cardiol Therapeutics Competitors Cabaletta Bio Competitors Climb Bio Competitors Tiziana Life Sciences Competitors Alpha Cognition Competitors Maxpro Capital Acquisition Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIVI) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
